ApprovedFDA approval

Mimrylo (rusfertide)

Takeda Pharmaceuticals America (TAK)

Marketer take

A new way to control erythrocytosis in polycythemia vera, so hematologist messaging will center on where it fits relative to phlebotomy and existing cytoreductive drugs.

Sponsor company
Takeda Pharmaceuticals America (TAK)
Indication
To treat erythrocytosis in adults with polycythemia vera
Therapeutic area
Hematology
Event
FDA approval
Date
Aug 28, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move